gw pharmaceuticals stock price today

How much is a share of GW Pharmaceuticals worth?

One share of GWPH stock can currently be purchased for approximately $218.96. How much money does GW Pharmaceuticals make? GW Pharmaceuticals has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year.

What does a hold rating mean for GW Pharmaceuticals (gwph)?

A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares. View analyst ratings for GW Pharmaceuticals or view top-rated stocks. What stocks does MarketBeat like better than GW Pharmaceuticals?

How do I get the latest gwph news and ratings?

Sign up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.

When will jazz stock close after it acquires GW?

Both companies' boards of directors have unanimously approved the acquisition. However, GW' shareholders must also vote in favor of the buyout. In addition, Jazz and GW will have to obtain regulatory approvals. However, the companies expect the transaction will close in the second quarter of 2021.

See more

Is GWPH a good stock to buy?

GW Pharma has 0.47% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How much is a share of GW Pharmaceuticals?

What is GW Pharmaceuticals' stock price today? One share of GWPH stock can currently be purchased for approximately $218.96.

What happened to GW Pharmaceuticals?

DUBLIN , May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.

Who is buying GW Pharmaceuticals?

Jazz Pharmaceuticals Plc(Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment.

How do I invest in GW Pharmaceuticals?

How to buy shares in GW PharmaceuticalsCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.

Is GW Pharmaceuticals publicly traded?

GW Leads the Pack Another top performing publicly traded cannabis company was GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $225 per share earlier this year.

How much did Jazz Pharmaceuticals pay for GW Pharmaceuticals?

$7.2 billionJazz agreed to pony up $7.2 billion for cannabinoid hotshot GW Pharmaceuticals, whose epilepsy med Epidiolex could be on its way to blockbuster sales. The deal will move Jazz into the epilepsy market, expanding its current offerings beyond sleep disorders and cancer.

Who bought Greenwich Pharmaceuticals?

Jazzplc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash.

Is Jazz Pharma a buy?

Jazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

What company owns Epidiolex?

GW Pharmaceuticals' (GWPH) cannabidiol (CBD) drug Epidiolex has been granted Food and Drug Administration approval for a new indication. Additionally, its previous approval has been expanded to cover a wider age range of patients.

What company owns Epidiolex?

Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals....GW Pharmaceuticals.TypeSubsidiaryHeadquartersCambridge, United KingdomKey peopleJustin Gover (CEO)ProductsEpidiolex (Epidyolex in Europe) Nabiximols (Sativex)12 more rows

Who owns Jazz Pharmaceuticals?

Bruce C. CozaddJazz PharmaceuticalsTypePublic companyKey peopleBruce C. Cozadd (Chairman & CEO)ProductsPharmaceutical drugsBrandsXyrem Erwinaze Defitelio FazaClo FazaClo HD Luvox CR Prialt VyxeosRevenueUS$1.618 billion (2017)13 more rows

Where is Jazz Pharmaceuticals headquarters?

IrelandJazz Pharmaceuticals / HeadquartersOur corporate headquarters are located in Dublin, Ireland. In the North America, we have offices in Palo Alto and Carlsbad, California; Philadelphia, Pennsylvania; Vancouver, British Columbia; and Mississauga, Ontario.

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0....

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the following people: Mr. Justin D. Gover , CEO & Exec. Director (Age 50, Pay $1.19M) ( LinkedIn Pr...

What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com . Justin Gover has an approval rating of 80% among GW Pharmaceuticals...

Who are some of GW Pharmaceuticals' key competitors?

Some companies that are related to GW Pharmaceuticals include Royalty Pharma (RPRX) , MERCK Kommanditgesellschaft auf Aktien (MKGAF) , Takeda Ph...

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC) , NVIDIA...

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $218.96.

How much money does GW Pharmaceuticals make?

GW Pharmaceuticals (NASDAQ:GWPH) has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceut...

How many employees does GW Pharmaceuticals have?

GW Pharmaceuticals employs 1,161 workers across the globe.

What happened

So what

Shares of GW Pharmaceuticals ( GWPH ) were skyrocketing 46.3% as of 10:45 a.m. EST on Wednesday. The huge gain came after Jazz Pharmaceuticals ( JAZZ -1.00% ) announced plans to acquire GW for $7.2 billion.

NASDAQ: GWPH

It's certainly not surprising in the least that GW Pharmaceuticals' shares took off today. Jazz's offer of $220 per share for GW represents a 50% premium to the closing price of the cannabinoid-focused biotech stock on Tuesday.

Now what

Why did Jazz choose to buy GW? Jazz Pharmaceuticals CEO Bruce Cozadd stated that GW's cannabinoid platform and pipeline "will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities."

Premium Investing Services

It's not a done deal just yet. Both companies' boards of directors have unanimously approved the acquisition. However, GW' shareholders must also vote in favor of the buyout. In addition, Jazz and GW will have to obtain regulatory approvals. However, the companies expect the transaction will close in the second quarter of 2021.